Weekly injection
Tirzepatide
Given once weekly. It acts on the GIP and GLP-1 pathways, and the dose is escalated gradually according to clinical response and tolerability.
Weight management
Comprehensive weight management, under medical supervision.
Excess weight is not treated with a single tool. It is assessed, understood and followed.
The programme combines medical assessment, nutritional follow-up, morphofunctional evaluation and, where clinically indicated, medication. The strategy is defined after understanding your history, not before.
What the programme includes
Each element is used according to what the patient needs. Not every patient requires all of them.
- Initial medical assessment
- Clinical history and background
- Clinical and morphofunctional assessment
- Personalised nutrition plan
- Regular medical follow-up
- Access to digital tools
- Medication where there is a medical indication
When medication may be considered
Medication is a tool inside the programme, never its starting point. It is considered in adults with obesity or overweight where there is a medical indication, after assessment and after ruling out the situations that require specific evaluation.
Scope of this care
No medication is prescribed without a prior medical assessment. Dose and progression are determined individually.
Treatments
Medication is a tool, not the plan.
These are the forms medication can take inside the programme. Which one applies, if any, is decided at the assessment.
Compounded formulation
Compounded GLP-1
Prepared by a compounding pharmacy against an individual prescription. Which option applies to you is clarified during the consultation.
Where indicated
Other medication
Not every plan is built around a GLP-1. Depending on the case, treatment may involve other medicines, or none at all.
Two options, one medical decision.
A brand-name medicine is the product registered by its manufacturer. A compounded formulation is prepared by a pharmacy against an individual prescription; it is not the brand-name product. Which one applies to you, at what dose and on what schedule, is decided during the consultation.
This practice is in Nicaragua and is regulated by MINSA, not by the FDA. Medicines available here may differ in presentation and availability from those in your home country, and nothing is dispensed without an in-person medical assessment.
None of these options is provided without a prior medical assessment.
Ask what applies to meComprehensive support
Choose the programme that matches your stage.
Treatment, medical follow-up and nutritional support in a single monthly fee.
Both programmes include
- 4 monthly doses
- 1 follow-up consultation per month
- Personalised nutrition plan
- Access to the patient app
- Preferential laboratory pricing
Equilibra
Steps 1–3 · 2.5 a 7.5 mgDesigned for the early stages of treatment and for gradual escalation according to clinical response and tolerability.
US$160/ month
Equilibra+
Steps 4–6 · 10 a 15 mgFor patients who, after medical follow-up, need to continue at higher stages.
US$200/ month
Treatment by dose
Supervision and administration according to your stage of treatment.
Start
2.5 mg
US$40
Adapt
5 mg
US$50
Progress
7.5 mg
US$60
Consolidate
10 mg
US$70
Optimise
12.5 mg
US$80
Full
15 mg
US$90
Not every patient needs to go through all six stages.
Dose and treatment progression are determined individually, under medical assessment. Not every patient needs to reach higher doses.
Prices in US dollars. Valid as of August 2026. Subject to change.
Not sure which programme fits your case?
Book a consultation and we will guide you.
Understand your treatment
Tirzepatide: one tool inside comprehensive care.
Tirzepatide acts on two metabolic signals, GIP and GLP-1. Their combined action can support appetite control, increase satiety and improve various metabolic parameters in appropriately selected patients. It is given once weekly.
Read the patient guide
Educational material. It is not a medical prescription and does not replace a professional assessment. Published in Spanish.
Adults with obesity or overweight where there is a medical indication. It may be particularly relevant for people with difficulty controlling appetite, metabolic abnormalities, type 2 diabetes, or excess weight associated with risk factors.
Treatment usually begins at a low dose so the body can adapt; later adjustments depend on each person’s response and tolerability.
The best dose is not always the highest. The right dose is the one that meets clinical goals with acceptable tolerability.
Tirzepatide requires medical assessment and prescription. Situations that require specific evaluation:
- Personal or family history of medullary thyroid carcinoma
- MEN-2 syndrome
- Pregnancy, breastfeeding, or plans to become pregnant
- Previous pancreatitis
- Gastroparesis
- Severe gastrointestinal disease
- Known allergy to tirzepatide or its components
If you use insulin or other glucose-lowering medication, medical adjustments may be required.
The most common effects are gastrointestinal: nausea, constipation, diarrhoea, fullness, reflux, belching, vomiting, marked reduction in appetite, fatigue or mild dizziness. Gradual escalation gives the body time to adapt.
Always tell the medical team about new or persistent effects.
These figures are average results from clinical trials and are not a promise of individual outcome. Results vary between patients.
Frequently asked
Do I have to take medication to join the programme?
No. Treatment depends on each patient’s situation, and some patients do not require medication.
How long does the programme last?
There is no single timeframe. It is defined during the assessment and adjusted as you progress.
What if the treatment does not agree with me?
Tell the medical team. Tolerability is one of the criteria used to adjust the regimen.
Other areas of care
Treatment starts by understanding your body, not by choosing a dose.
Book a consultation and let us work out together which strategy may be right for you.